Butantan biomedical institute in Brazil's Sao Paulo state is in talks to sell a locally manufactured COVID-19 vaccine developed by Chinese biopharmaceutical company Sinovac Biotech (Nasdaq:SVA) to other countries in South America and Africa, Reuters news agency reported on Thursday.
The Brazilian federal government has not ordered more of Sinovac's COVID-19 vaccine doses, but Butantan has contracts to supply the vaccine directly to Brazilian states.
Currently, Butantan is producing Sinovac's CoronaVac shot using inputs imported from China. It aims to complete a factory for 100% local production by early next year.
Earlier this month, Butantan completed its contract to deliver 100 million doses of CoronaVac to Brazil's Health Ministry, without another deal in place.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses